Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab in hormone-refractory prostate cancer
NCT02480010Phase 2Terminated
- Sponsor
- Roche
- Start
- Sep 2003
- Primary completion
- Sep 2005
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of pertuzumab in prostate cancer (PCa) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With Confirmed, Objective Response, Non-Response or Progressive Disease by PSA Levels at 24 weeks. Started Sep 2003; status: terminated.
02
Drugs
pertuzumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02480010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02480010.